Breast Positioning Articles & Analysis
8 articles found
The majority of patients with metastatic breast cancer (MBC) have hormone receptor-positive HER2-negative disease. ...
Two are for HER2 breast cancer ADCs. T-DM1(Ado-trastuzumab Emtansine) T-DM1 is the first ADC drug to target HER2-positive breast cancer. ...
On February 24, 2023, The NMPA approved Enhertu, an injectable drug developed jointly by AstraZeneca and Daiichi Sankyo, for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have previously received one or more anti-HER2 drugs. ...
Worldwide, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer deaths in women, with over 650,000 deaths in 2020.1,2 Human epidermal growth factor receptor 2 (HER2)-targeted agents have improved outcomes in HER2-positive breast cancer, but most patients in first-line therapy do not respond to current therapies, ...
Patient with positive family history of breast cancer and ovarian cancer. September 2003 mammogram reported benign micro calcifications. August 2007 patient presented with a palpable mass in lateral aspect of left ...
The lysine residue of trastuzumab is linked to DM1 via a non-cleavable linker containing N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), an ADC (T-DM1, Kadcyla) authorized by the FDA in 2013 for treatment in HER2-positive breast cancer patients. This novel ADC is very effective in HER2-positive breast cancer ...
Traditional small molecule-based ADCs are showing meaningful advantages in difficult-to-treat indications such as triple-negative breast cancer, and new drug design paradigms are emerging, such as new payload classes including oligonucleotides, proteins, and degradates. ...
In 2013, Kadcyla was approved by the FDA for the treatment of HER2-positive breast cancer. The appearance of these two drugs has reignited the enthusiasm for ADC research. ...